BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259. [PMID: 17317837 DOI: 10.1158/1078-0432.ccr-06-2309] [Cited by in Crossref: 792] [Cited by in F6Publishing: 395] [Article Influence: 52.8] [Reference Citation Analysis]
Number Citing Articles
1 Rich JN. The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. Future Neurol 2008;3:265-73. [PMID: 19763280 DOI: 10.2217/14796708.3.3.265] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, Mikkelsen T. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 2010;99:237-42. [PMID: 20151176 DOI: 10.1007/s11060-010-0121-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
3 Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol 2010;12:321-33. [PMID: 20842591 DOI: 10.1007/s11940-010-0078-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
4 Tosoni A, Franceschi E, Poggi R, Brandes AA. Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. Curr Treat Options Oncol 2016;17:49. [PMID: 27461038 DOI: 10.1007/s11864-016-0422-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
5 Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265-314. [PMID: 22084619 DOI: 10.4137/cmo.s7685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
6 Stokum JA, Gerzanich V, Sheth KN, Kimberly WT, Simard JM. Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. Annu Rev Pharmacol Toxicol 2020;60:291-309. [PMID: 31914899 DOI: 10.1146/annurev-pharmtox-010919-023429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
7 Kumar NN, Pizzo ME, Nehra G, Wilken-Resman B, Boroumand S, Thorne RG. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjug Chem 2018;29:3937-66. [PMID: 30265523 DOI: 10.1021/acs.bioconjchem.8b00548] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol 2015;17:784-800. [PMID: 25543124 DOI: 10.1093/neuonc/nou322] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
9 Zhukova N, Rajagopal R, Lam A, Coleman L, Shipman P, Walwyn T, Williams M, Sullivan M, Campbell M, Bhatia K, Gottardo NG, Hansford JR. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. Cancer Med 2019;8:40-50. [PMID: 30569607 DOI: 10.1002/cam4.1799] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
10 Chung EY, Dews M, Maity A, Thomas-Tikhonenko A. Aiding and ABT'ing Treatment for Glioblastoma. Cancer Biol Ther 2007;6:802-4. [PMID: 17568181 DOI: 10.4161/cbt.6.5.4431] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Roy S, Lahiri D, Maji T, Biswas J. Recurrent Glioblastoma: Where we stand. South Asian J Cancer 2015;4:163-73. [PMID: 26981507 DOI: 10.4103/2278-330X.175953] [Cited by in Crossref: 59] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
12 Hsu YH, Huang Z, Ferl GZ, Ng CM. GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. PLoS One 2015;10:e0118421. [PMID: 25786263 DOI: 10.1371/journal.pone.0118421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Blesa JM, Mollá SB, Esparcia MF, Ortells JM, Godoy MP, Das AM, Magan BM, Pulla MP, Sanchez JL, Canales JB, Candel VA. Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab. Case Rep Oncol 2012;5:676-81. [PMID: 23341811 DOI: 10.1159/000341852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
14 Bowden SG, Han SJ. The Evolving Role of the Oncologic Neurosurgeon: Looking Beyond Extent of Resection in the Modern Era. Front Oncol 2018;8:406. [PMID: 30319971 DOI: 10.3389/fonc.2018.00406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM, Ruoslahti E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A 2011;108:17450-5. [PMID: 21969599 DOI: 10.1073/pnas.1114518108] [Cited by in Crossref: 241] [Cited by in F6Publishing: 224] [Article Influence: 21.9] [Reference Citation Analysis]
16 Funakoshi Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Takigawa K, Mizoguchi M. Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. Pharmaceuticals (Basel) 2020;13:E470. [PMID: 33339404 DOI: 10.3390/ph13120470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 AlDeghaither D, Smaglo BG, Weiner LM. Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 2015;55 Suppl 3:S4-20. [PMID: 25707963 DOI: 10.1002/jcph.407] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
18 Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist 2014;19:75-81. [PMID: 24309981 DOI: 10.1634/theoncologist.2013-0101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
19 Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 2011;117:5351-8. [PMID: 21590689 DOI: 10.1002/cncr.26188] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
20 Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-60. [PMID: 18436627 DOI: 10.1215/15228517-2008-009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
21 Goyal P, Tenenbaum M, Gupta S, Kochar PS, Bhatt AA, Mangla M, Kumar Y, Mangla R. Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab. Quant Imaging Med Surg 2018;8:268-79. [PMID: 29774180 DOI: 10.21037/qims.2018.04.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Vargo JA, Snelling BM, Ghareeb ER, John K, Frame JN, Schmidt JH, Peters KB. Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. J Neurooncol 2011;104:595-8. [PMID: 21221711 DOI: 10.1007/s11060-010-0519-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
23 Odia Y, Shih JH, Kreisl TN, Fine HA. Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. J Neurooncol 2014;120:431-40. [PMID: 25098701 DOI: 10.1007/s11060-014-1571-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
24 Yang SB, Gao KD, Jiang T, Cheng SJ, Li WB. Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. Oncotarget 2017;8:57337-44. [PMID: 28915674 DOI: 10.18632/oncotarget.16924] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
25 Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009;9:444. [PMID: 20015387 DOI: 10.1186/1471-2407-9-444] [Cited by in Crossref: 122] [Cited by in F6Publishing: 126] [Article Influence: 9.4] [Reference Citation Analysis]
26 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
27 Bendszus M, Platten M. [Neuroradiological response criteria for malignant gliomas]. Nervenarzt 2010;81:950-5. [PMID: 20669003 DOI: 10.1007/s00115-010-2959-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009;11:448-58, 2 p following 458. [PMID: 19412429 DOI: 10.1593/neo.09230] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
29 Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med 2014; 4(4): 58-67 [PMID: 25414818 DOI: 10.5493/wjem.v4.i4.58] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745. [PMID: 19114704 DOI: 10.1200/jco.2008.16.3055] [Cited by in Crossref: 1077] [Cited by in F6Publishing: 583] [Article Influence: 76.9] [Reference Citation Analysis]
31 Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen ZR, Mardor Y. Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS One 2012;7:e52008. [PMID: 23251672 DOI: 10.1371/journal.pone.0052008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
32 Lukas RV, Boire A, Nicholas MK. Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther 2009;2:115-33. [PMID: 20616900 DOI: 10.2147/ott.s3027] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
33 Gardner SL, Ahmed N, Okada H. Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant 2010;16:S75-81. [PMID: 19896544 DOI: 10.1016/j.bbmt.2009.11.003] [Reference Citation Analysis]
34 Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, Delle Monache S, Maturo MG, Sferra R, Chiodelli P, Rusnati M, Cantoni A, Castelli R, Vacondio F, Lodola A, Tognolini M. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget 2018;9:24347-63. [PMID: 29849945 DOI: 10.18632/oncotarget.25272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
35 Wu Z, Wang D, Zeng F, Zhang Y, Zhu G, Ma Y, Song B, Lui S, Wu M. High IER5 Gene Expression Is Associated With Poor Prognosis in Glioma Patients. Front Cell Dev Biol 2021;9:679684. [PMID: 34222249 DOI: 10.3389/fcell.2021.679684] [Reference Citation Analysis]
36 Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-75. [PMID: 18539480 DOI: 10.1016/j.smim.2008.04.001] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 8.5] [Reference Citation Analysis]
37 Baskin DS, Sharpe MA, Nguyen L, Helekar SA. Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device. Front Oncol 2021;11:708017. [PMID: 34367992 DOI: 10.3389/fonc.2021.708017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines 2016;4:E24. [PMID: 28536391 DOI: 10.3390/biomedicines4040024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
39 Shuford S, Lipinski L, Abad A, Smith AM, Rayner M, O'Donnell L, Stuart J, Mechtler LL, Fabiano AJ, Edenfield J, Kanos C, Gardner S, Hodge P, Lynn M, Butowski NA, Han SJ, Redjal N, Crosswell HE, Vibat CRT, Holmes L, Gevaert M, Fenstermaker RA, DesRochers TM. Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. Neurooncol Adv 2021;3:vdab065. [PMID: 34142085 DOI: 10.1093/noajnl/vdab065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Guo J, Cai H, Liu X, Zheng J, Liu Y, Gong W, Chen J, Xi Z, Xue Y. Long Non-coding RNA LINC00339 Stimulates Glioma Vasculogenic Mimicry Formation by Regulating the miR-539-5p/TWIST1/MMPs Axis. Mol Ther Nucleic Acids 2018;10:170-86. [PMID: 29499931 DOI: 10.1016/j.omtn.2017.11.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
41 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2012;106:111-9. [PMID: 21706273 DOI: 10.1007/s11060-011-0638-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
42 Balaña C, Capellades J, Teixidor P, Roussos I, Ballester R, Cuello M, Arellano A, Florensa R, Rosell R. Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment. Clin Transl Oncol 2007;9:797-803. [PMID: 18158984 DOI: 10.1007/s12094-007-0142-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zheng X, Tang Q, Ren L, Liu J, Li W, Fu W, Wang J, Du G. A narrative review of research progress on drug therapies for glioblastoma multiforme. Ann Transl Med 2021;9:943. [PMID: 34350258 DOI: 10.21037/atm-20-8017] [Reference Citation Analysis]
44 Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013;19:4717-27. [PMID: 23857604 DOI: 10.1158/1078-0432.CCR-12-3891] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
45 Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett 2017;14:1141-6. [PMID: 28693286 DOI: 10.3892/ol.2017.6251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
46 Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol 2010;12:985-90. [PMID: 20363768 DOI: 10.1093/neuonc/noq033] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
47 Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD; North American Brain Tumor Consortium. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 2008;10:631-42. [PMID: 18559968 DOI: 10.1215/15228517-2008-021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
48 Mantica M, Pritchard A, Lieberman F, Drappatz J. Retrospective study of nivolumab for patients with recurrent high grade gliomas. J Neurooncol 2018;139:625-31. [PMID: 29779086 DOI: 10.1007/s11060-018-2907-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
49 Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, Guidi M, Terrasi M, Cetto GL, Surmacz E. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol 2010;20:481-9. [PMID: 19775291 DOI: 10.1111/j.1750-3639.2009.00323.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
50 Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8. [PMID: 18182667 DOI: 10.1200/JCO.2007.13.3652] [Cited by in Crossref: 205] [Cited by in F6Publishing: 113] [Article Influence: 14.6] [Reference Citation Analysis]
51 Hale JS, Sinyuk M, Rich JN, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol 2013;2:319-30. [PMID: 24379973 DOI: 10.2217/cns.13.23] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
52 Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int 2015;2015:215135. [PMID: 26448930 DOI: 10.1155/2015/215135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
53 Xu X, Stockhammer F, Schmitt M. Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol 2012;2012:764213. [PMID: 22474481 DOI: 10.1155/2012/764213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
54 Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell 2010;1:638-55. [PMID: 21203936 DOI: 10.1007/s13238-010-0078-y] [Cited by in Crossref: 141] [Cited by in F6Publishing: 134] [Article Influence: 11.8] [Reference Citation Analysis]
55 Wang Y, Xing D, Zhao M, Wang J, Yang Y. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review. PLoS One 2016;11:e0152170. [PMID: 27007828 DOI: 10.1371/journal.pone.0152170] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
56 Zhou Z, Wen L, Lai M, Shan C, Wang J, Wang R, Li H, Chen L, Cai L, Zhou M, Zhou C. Increased M1 Macrophages Infiltration Correlated With Poor Survival Outcomes and Radiation Response in Gliomas. Dose Response 2020;18:1559325820964991. [PMID: 33117094 DOI: 10.1177/1559325820964991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 2012;107:155-64. [PMID: 21986722 DOI: 10.1007/s11060-011-0722-2] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 9.2] [Reference Citation Analysis]
58 Graceffa D, Maiani E, Pace A, Solivetti FM, Elia F, De Mutiis C, Bonifati C. Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. Case Rep Rheumatol 2012;2012:208606. [PMID: 23243547 DOI: 10.1155/2012/208606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
59 Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013;13:347. [PMID: 23529375 DOI: 10.1007/s11910-013-0347-2] [Cited by in Crossref: 88] [Cited by in F6Publishing: 75] [Article Influence: 9.8] [Reference Citation Analysis]
60 Kuramitsu S, Motomura K, Natsume A, Wakabayashi T. Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report. NMC Case Rep J 2015;2:40-5. [PMID: 28663961 DOI: 10.2176/nmccrj.2014-0025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
61 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol 2012;69:1507-18. [PMID: 22392572 DOI: 10.1007/s00280-012-1854-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
62 Li Y, Hou M, Lu G, Ciccone N, Wang X, Zhang H. The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. PLoS One 2016;11:e0168264. [PMID: 28005980 DOI: 10.1371/journal.pone.0168264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12:508-16. [PMID: 20406901 DOI: 10.1093/neuonc/nop063] [Cited by in Crossref: 18] [Cited by in F6Publishing: 83] [Article Influence: 1.5] [Reference Citation Analysis]
64 Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Schmainda KM. Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume. Magn Reson Med 2012;68:1266-72. [PMID: 22213469 DOI: 10.1002/mrm.23315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
65 Newton HB. Glioblastoma multiforme. Curr Treat Options Neurol 2008;10:285-94. [PMID: 18579015 DOI: 10.1007/s11940-008-0031-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
66 Cea V, Sala C, Verpelli C. Antiangiogenic therapy for glioma. J Signal Transduct 2012;2012:483040. [PMID: 22830012 DOI: 10.1155/2012/483040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
67 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:401-9. [PMID: 21324937 DOI: 10.1093/neuonc/noq206] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
68 Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol 2011;103:673-80. [PMID: 21038110 DOI: 10.1007/s11060-010-0444-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
69 Li J, Di C, Mattox AK, Wu L, Adamson DC. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med 2010;3:111-27. [PMID: 23226047 DOI: 10.2147/PGPM.S6852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
70 Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo KM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro Oncol 2016;18:735-43. [PMID: 26538618 DOI: 10.1093/neuonc/nov268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
71 de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29:2689-95. [PMID: 21606416 DOI: 10.1200/JCO.2010.34.1636] [Cited by in Crossref: 144] [Cited by in F6Publishing: 71] [Article Influence: 13.1] [Reference Citation Analysis]
72 DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012;18:2930-42. [PMID: 22472177 DOI: 10.1158/1078-0432.CCR-11-2390] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
73 Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. Cancer Res Treat 2017;49:129-40. [PMID: 27188199 DOI: 10.4143/crt.2015.466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
75 Kim SS, Rait A, Kim E, Pirollo KF, Chang EH. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 2015;11:301-11. [PMID: 25240597 DOI: 10.1016/j.nano.2014.09.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
76 Nolen SC, Lee B, Shantharam S, Yu HJ, Su L, Billimek J, Bota DA. The effects of sequential treatments on hippocampal volumes in malignant glioma patients. J Neurooncol 2016;129:433-41. [PMID: 27393350 DOI: 10.1007/s11060-016-2188-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Zhu Y, Young GS, Xue Z, Huang RY, You H, Setayesh K, Hatabu H, Cao F, Wong ST. Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation. Acad Radiol 2012;19:977-85. [PMID: 22591720 DOI: 10.1016/j.acra.2012.03.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
78 Kievit FM, Veiseh O, Fang C, Bhattarai N, Lee D, Ellenbogen RG, Zhang M. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano 2010;4:4587-94. [PMID: 20731441 DOI: 10.1021/nn1008512] [Cited by in Crossref: 161] [Cited by in F6Publishing: 150] [Article Influence: 13.4] [Reference Citation Analysis]
79 Katsoulakis E, Beal K, Yamada Y. Image guidance in malignant gliomas: a focused strategy. CNS Oncol 2012;1:131-6. [PMID: 25057863 DOI: 10.2217/cns.12.21] [Reference Citation Analysis]
80 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
81 Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y, Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, Evans JJ, Judy K, Farrell CJ, Andrews DW. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. J Neurooncol 2018;137:171-7. [PMID: 29235052 DOI: 10.1007/s11060-017-2709-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
82 Zhang J, Winters K, Kiser K, Baboli M, Kim SG. Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: Comparison with conventional DCE-MRI. PLoS One 2020;15:e0234520. [PMID: 32520950 DOI: 10.1371/journal.pone.0234520] [Reference Citation Analysis]
83 Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. BioDrugs 2009;23:25-35. [PMID: 19344189 DOI: 10.2165/00063030-200923010-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
84 Nagaiah G, Almubarak M, Khan M, Altaha R. Cerebrospinal Fluid Leak During Treatment With Bevacizumab and Irinotecan After Carmustine-Impregnated Wafers Placement in Patients With Grade 2 Oligodendroglioma and Glioblastoma Multiforme: Report of Two Cases and Review of Literature. Cancer Investigation 2010;28:1048-53. [DOI: 10.3109/07357907.2010.483499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Waerzeggers Y, Monfared P, Viel T, Faust A, Kopka K, Schäfers M, Tavitian B, Winkeler A, Jacobs A. Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol 2011;84 Spec No 2:S168-78. [PMID: 22433827 DOI: 10.1259/bjr/66405626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Ling G, Wang S, Song Z, Sun X, Liu Y, Jiang X, Cai Y, Du M, Ke Y. Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG. Cancer Biol Ther 2011;12:978-88. [PMID: 22104964 DOI: 10.4161/cbt.12.11.18155] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
87 Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63. [PMID: 19167838 DOI: 10.1016/j.ijrobp.2008.10.043] [Cited by in Crossref: 261] [Cited by in F6Publishing: 236] [Article Influence: 20.1] [Reference Citation Analysis]
88 Ferla R, Bonomi M, Otvos L Jr, Surmacz E. Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. BMC Cancer 2011;11:303. [PMID: 21771332 DOI: 10.1186/1471-2407-11-303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
89 Pan E, Yu D, Yue B, Potthast L, Chowdhary S, Smith P, Chamberlain M. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol 2012;110:111-8. [PMID: 22832897 DOI: 10.1007/s11060-012-0943-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
90 Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int 2015;6:S9-S44. [PMID: 25722939 DOI: 10.4103/2152-7806.151331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
91 Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 2012;7:93-103. [PMID: 23055947 DOI: 10.2147/CE.S29001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.5] [Reference Citation Analysis]
92 Zheng W, Chen Q, Liu H, Hu S, Zhou Y, Bai Y, Zhang J, Pan Y, Shao C. CD81 Enhances Radioresistance of Glioblastoma by Promoting Nuclear Translocation of Rad51. Cancers (Basel) 2021;13:1998. [PMID: 33919192 DOI: 10.3390/cancers13091998] [Reference Citation Analysis]
93 Ruiz-Sánchez D, Peinado II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Peña-Díaz J. Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncol Lett 2016;12:1935-40. [PMID: 27588142 DOI: 10.3892/ol.2016.4871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
94 Schweneker K, Clemm C, Brügel M, Souvatzoglou M, Hermisson M, Schmidt-Graf F, Zimmer C, Peschel C, Jost PJ. Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature. Exp Hematol Oncol 2014;3:29. [PMID: 25954595 DOI: 10.1186/2162-3619-3-29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
95 Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 2009;11:92-5. [PMID: 18757774 DOI: 10.1215/15228517-2008-071] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
96 Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26:2839-2845. [PMID: 18539962 DOI: 10.1200/jco.2007.15.1829] [Cited by in Crossref: 490] [Cited by in F6Publishing: 262] [Article Influence: 35.0] [Reference Citation Analysis]
97 Javerzat S, Godard V, Bikfalvi A. Balancing risks and benefits of anti-angiogenic drugs for malignant glioma. Future Neurology 2013;8:159-74. [DOI: 10.2217/fnl.12.91] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Arrillaga-Romany I, Norden AD. Antiangiogenic therapies for glioblastoma. CNS Oncol 2014;3:349-58. [PMID: 25363007 DOI: 10.2217/cns.14.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
99 Chen X, Tai L, Gao J, Qian J, Zhang M, Li B, Xie C, Lu L, Lu W, Lu W. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation. J Control Release 2015;218:29-35. [PMID: 26428461 DOI: 10.1016/j.jconrel.2015.09.061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
100 Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009;6:447-57. [PMID: 19560735 DOI: 10.1016/j.nurt.2009.04.001] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 11.1] [Reference Citation Analysis]
101 Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 2013;8:e74345. [PMID: 24069296 DOI: 10.1371/journal.pone.0074345] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
102 Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009;9:1815-36. [PMID: 19951140 DOI: 10.1586/ern.09.116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
103 Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E; North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 2009;92:165-75. [PMID: 19066728 DOI: 10.1007/s11060-008-9749-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
104 Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.J Neurooncol. 2014;117:337-345. [PMID: 24504501 DOI: 10.1007/s11060-014-1394-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
105 Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, Zadeh G. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol 2014;16:868-79. [PMID: 24759636 DOI: 10.1093/neuonc/nou040] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
106 Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 2013;15:242-50. [PMID: 23243055 DOI: 10.1093/neuonc/nos295] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 6.5] [Reference Citation Analysis]
107 Curtin JF, Candolfi M, Xiong W, Lowenstein PR, Castro MG. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther 2008;7:439-48. [PMID: 18347132 DOI: 10.1158/1535-7163.MCT-07-2328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
108 Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012;22:21-35. [PMID: 22789536 DOI: 10.1016/j.ccr.2012.05.037] [Cited by in Crossref: 389] [Cited by in F6Publishing: 352] [Article Influence: 38.9] [Reference Citation Analysis]
109 Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008;8:541-53. [PMID: 18352856 DOI: 10.1517/14712598.8.4.541] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
110 Arakawa Y, Mizowaki T, Murata D, Fujimoto K, Kikuchi T, Kunieda T, Takahashi JC, Takagi Y, Miyamoto S. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. Neurol Med Chir (Tokyo) 2013;53:779-85. [PMID: 24140770 DOI: 10.2176/nmc.oa2013-0211] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
111 Mayer T, Lacy J, Baehring J. A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma. Clin Med Oncol 2008;2:455-9. [PMID: 21892317 DOI: 10.4137/cmo.s827] [Reference Citation Analysis]
112 Law M. Advanced imaging techniques in brain tumors. Cancer Imaging 2009;9 Spec No A:S4-9. [PMID: 19965287 DOI: 10.1102/1470-7330.2009.9002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
113 Ranjan S, Skorupan N, Ye X, Sivakumar A, Yankulina O, Kamson D, Grossman SA, Dzaye O, Holdhoff M. Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. Neurooncol Pract 2020;7:52-8. [PMID: 32257284 DOI: 10.1093/nop/npz022] [Reference Citation Analysis]
114 Li Z, Chen Y, An T, Liu P, Zhu J, Yang H, Zhang W, Dong T, Jiang J, Zhang Y, Jiang M, Yang X. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway. J Exp Clin Cancer Res 2019;38:139. [PMID: 30922391 DOI: 10.1186/s13046-019-1134-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
115 Di Nunno V, Franceschi E, Tosoni A, Gatto L, Lodi R, Bartolini S, Brandes AA. Glioblastoma: Emerging Treatments and Novel Trial Designs. Cancers (Basel) 2021;13:3750. [PMID: 34359651 DOI: 10.3390/cancers13153750] [Reference Citation Analysis]
116 Katz A, Calabrich A, Dos Santos Fernandes G, Sakis Novis YA. Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab. Case Rep Oncol 2009;2:57-60. [PMID: 20740146 DOI: 10.1159/000208378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Ononiwu C, Mehta V, Bettegowda C, Jallo G. Pediatric spinal glioblastoma multiforme: current treatment strategies and possible predictors of survival. Childs Nerv Syst 2012;28:715-20. [PMID: 22307824 DOI: 10.1007/s00381-012-1705-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
118 Batich KA, Sampson JH. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother 2014;15:2047-61. [PMID: 25139628 DOI: 10.1517/14656566.2014.947266] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
119 Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008;88:339-47. [PMID: 18389177 DOI: 10.1007/s11060-008-9573-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 5.9] [Reference Citation Analysis]
120 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5:e8. [PMID: 18215105 DOI: 10.1371/journal.pmed.0050008] [Cited by in Crossref: 401] [Cited by in F6Publishing: 383] [Article Influence: 28.6] [Reference Citation Analysis]
121 Friedmann-Morvinski D, Verma IM. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 2014;15:244-253. [PMID: 24531722 DOI: 10.1002/embr.201338254] [Cited by in Crossref: 229] [Cited by in F6Publishing: 220] [Article Influence: 28.6] [Reference Citation Analysis]
122 Soda Y, Myskiw C, Rommel A, Verma IM. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 2013;91:439-48. [PMID: 23512266 DOI: 10.1007/s00109-013-1019-z] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 10.6] [Reference Citation Analysis]
123 Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, Fine HA. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol 2016;5:59-67. [PMID: 26860632 DOI: 10.2217/cns-2015-0010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
124 Michael JS, Lee BS, Zhang M, Yu JS. Nanotechnology for Treatment of Glioblastoma Multiforme. J Transl Int Med 2018;6:128-33. [PMID: 30425948 DOI: 10.2478/jtim-2018-0025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
125 Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:143-51. [PMID: 21084434 DOI: 10.1093/neuonc/noq151] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
126 Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol 2008;10:262-7. [PMID: 18490242 DOI: 10.1007/s12094-008-0195-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
127 Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics 2017;14:307-20. [PMID: 28108885 DOI: 10.1007/s13311-016-0507-6] [Cited by in Crossref: 125] [Cited by in F6Publishing: 110] [Article Influence: 25.0] [Reference Citation Analysis]
128 Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, Galanis E, Sarkaria JN, Anastasiadis PZ. Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One 2013;8:e56505. [PMID: 23457577 DOI: 10.1371/journal.pone.0056505] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
129 Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008;4:372-9. [PMID: 18232053 DOI: 10.1002/smll.200700784] [Cited by in Crossref: 243] [Cited by in F6Publishing: 217] [Article Influence: 17.4] [Reference Citation Analysis]
130 Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist 2011;16:1435-9. [PMID: 21948651 DOI: 10.1634/theoncologist.2011-0047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
131 Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 2011;9:414-27. [PMID: 21464146 DOI: 10.6004/jnccn.2011.0038] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 7.0] [Reference Citation Analysis]
132 Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. J Neurooncol 2015;121:217-24. [PMID: 25407389 DOI: 10.1007/s11060-014-1665-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
133 Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncol 2018;7:7-13. [PMID: 29388793 DOI: 10.2217/cns-2017-0025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
134 Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-36. [PMID: 18953493 DOI: 10.1007/s11060-008-9718-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 186] [Article Influence: 14.6] [Reference Citation Analysis]
135 Ahluwalia MS, Chang SM. Medical therapy of gliomas. J Neurooncol 2014;119:503-12. [PMID: 24986089 DOI: 10.1007/s11060-014-1495-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
136 Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-22. [PMID: 19349600 DOI: 10.1212/01.wnl.0000345668.03039.90] [Cited by in Crossref: 168] [Cited by in F6Publishing: 161] [Article Influence: 12.9] [Reference Citation Analysis]
137 Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009;92:149-55. [PMID: 19043778 DOI: 10.1007/s11060-008-9745-8] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 7.3] [Reference Citation Analysis]
138 Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA. Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin 2014;1:59-77. [PMID: 26675306 DOI: 10.1016/j.bbacli.2014.06.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
139 Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L. Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol 2017;135:99-105. [PMID: 28667595 DOI: 10.1007/s11060-017-2553-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
140 Stegh AH. Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) 2013;5:48-65. [PMID: 22858688 DOI: 10.1039/c2ib20104f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
141 Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 2014;119:135-40. [PMID: 24803001 DOI: 10.1007/s11060-014-1460-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
142 Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, Lennartsson J, Zhu C, Qu Y, Fang C, Hua J, Matsuo O, Fong GH, Ding H, Cao Y, Becker KG, Nash A, Heldin CH, Li X. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008;118:913-23. [PMID: 18259607 DOI: 10.1172/JCI33673] [Cited by in Crossref: 22] [Cited by in F6Publishing: 81] [Article Influence: 1.6] [Reference Citation Analysis]
143 Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5:610-20. [PMID: 19826401 DOI: 10.1038/nrneurol.2009.159] [Cited by in Crossref: 173] [Cited by in F6Publishing: 159] [Article Influence: 13.3] [Reference Citation Analysis]
144 Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 2013;33:162-74. [PMID: 22989076 DOI: 10.1111/j.1440-1789.2012.01344.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
145 Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 2012;107:213-21. [PMID: 21997879 DOI: 10.1007/s11060-011-0740-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
146 Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 2011;13:1324-30. [PMID: 21954442 DOI: 10.1093/neuonc/nor145] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
147 Wang W, Li Z, Duan J, Wang C, Fang Y, Yang XD. In vitro enhancement of dendritic cell-mediated anti-glioma immune response by graphene oxide. Nanoscale Res Lett 2014;9:311. [PMID: 25024678 DOI: 10.1186/1556-276X-9-311] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
148 Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008;5:634-44. [PMID: 18711427 DOI: 10.1038/ncponc1204] [Cited by in Crossref: 141] [Cited by in F6Publishing: 135] [Article Influence: 10.1] [Reference Citation Analysis]
149 Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. J Neurooncol 2011;103:353-60. [PMID: 20848300 DOI: 10.1007/s11060-010-0397-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
150 Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28:1168-74. [PMID: 20124186 DOI: 10.1200/JCO.2009.23.2595] [Cited by in Crossref: 325] [Cited by in F6Publishing: 157] [Article Influence: 27.1] [Reference Citation Analysis]
151 Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 2009;15:519-30. [PMID: 19889578 DOI: 10.1016/j.molmed.2009.09.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
152 Vallon M, Chang J, Zhang H, Kuo CJ. Developmental and pathological angiogenesis in the central nervous system. Cell Mol Life Sci 2014;71:3489-506. [PMID: 24760128 DOI: 10.1007/s00018-014-1625-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
153 Zhang C, Chen W, Zhang X, Huang B, Chen A, He Y, Wang J, Li X. Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes. Sci Rep 2016;6:23056. [PMID: 26976322 DOI: 10.1038/srep23056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
154 Pichler R, Horninger W, Aigner F, Heidegger I. [Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years]. Urologe A 2016;55:381-5. [PMID: 26471795 DOI: 10.1007/s00120-015-3976-z] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Huang GH, Pei YC, Yang L, Mou KJ, Tang JH, Xiang Y, Liu J, Lv SQ. Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas. Oncol Lett 2020;20:75-84. [PMID: 32565936 DOI: 10.3892/ol.2020.11542] [Reference Citation Analysis]
156 Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6:570-586. [PMID: 19560746 DOI: 10.1016/j.nurt.2009.04.006] [Cited by in Crossref: 109] [Cited by in F6Publishing: 88] [Article Influence: 8.4] [Reference Citation Analysis]
157 Li LY, Jiang H, Xie YM, Liao LD, Cao HH, Xu XE, Chen B, Zeng FM, Zhang YL, Du ZP, Chen H, Huang W, Jia W, Zheng W, Xie JJ, Li EM, Xu LY. Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation. Oncotarget 2015;6:15940-52. [PMID: 25909284 DOI: 10.18632/oncotarget.3612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
158 Zhang L, Xu Y, Sun J, Chen W, Zhao L, Ma C, Wang Q, Sun J, Huang B, Zhang Y, Li X, Qu X. M2-like tumor-associated macrophages drive vasculogenic mimicry through amplification of IL-6 expression in glioma cells. Oncotarget 2017;8:819-32. [PMID: 27903982 DOI: 10.18632/oncotarget.13661] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
159 Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007;25:4033-4042. [PMID: 17827451 DOI: 10.1200/jco.2007.11.3985] [Cited by in Crossref: 106] [Cited by in F6Publishing: 34] [Article Influence: 7.1] [Reference Citation Analysis]
160 Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 2014;116:533-41. [PMID: 24293233 DOI: 10.1007/s11060-013-1317-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
161 Chang JH, Kim CY, Choi BS, Kim YJ, Kim JS, Kim IA. Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group. J Korean Neurosurg Soc 2014;55:5-11. [PMID: 24570811 DOI: 10.3340/jkns.2014.55.1.5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
162 Li T, Ge G, Zhang H, Wang R, Liu Y, Zhang Q, Yue Z, Ma W, Li W, Zhang J, Yang H, Wang P, Zhao J, Fang Y, Xie Q, Wang M, Li Y, Zhu H, Li H. HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma. Eur J Pharm Sci 2021;167:106017. [PMID: 34555448 DOI: 10.1016/j.ejps.2021.106017] [Reference Citation Analysis]
163 Ross JL, Cooper LAD, Kong J, Gutman D, Williams M, Tucker-Burden C, McCrary MR, Bouras A, Kaluzova M, Dunn WD Jr, Duong D, Hadjipanayis CG, Brat DJ. 5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins. Sci Rep 2017;7:15593. [PMID: 29142297 DOI: 10.1038/s41598-017-15849-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
164 de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233-242. [PMID: 20167811 DOI: 10.1093/neuonc/nop027] [Cited by in Crossref: 364] [Cited by in F6Publishing: 338] [Article Influence: 30.3] [Reference Citation Analysis]
165 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012;26:756-784. [PMID: 22508724 DOI: 10.1101/gad.187922.112.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ, Boockvar JA. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg. 2012;77:130-134. [PMID: 22405392 DOI: 10.1016/j.wneu.2011.05.056] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
167 Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-73. [PMID: 18981004 DOI: 10.1158/1078-0432.CCR-08-0260] [Cited by in Crossref: 133] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
168 Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 2010;96:259-69. [PMID: 19593660 DOI: 10.1007/s11060-009-9957-6] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
169 Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6. [PMID: 19822869 DOI: 10.1212/WNL.0b013e3181bc0184] [Cited by in Crossref: 208] [Cited by in F6Publishing: 148] [Article Influence: 16.0] [Reference Citation Analysis]
170 Schonberg DL, Lubelski D, Miller TE, Rich JN. Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med 2014;39:82-101. [PMID: 23831316 DOI: 10.1016/j.mam.2013.06.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 11.2] [Reference Citation Analysis]
171 Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 2011;108:4274-80. [PMID: 21262804 DOI: 10.1073/pnas.1016030108] [Cited by in Crossref: 344] [Cited by in F6Publishing: 315] [Article Influence: 31.3] [Reference Citation Analysis]
172 Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 2016;113:4470-5. [PMID: 27044097 DOI: 10.1073/pnas.1525349113] [Cited by in Crossref: 157] [Cited by in F6Publishing: 154] [Article Influence: 26.2] [Reference Citation Analysis]
173 Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol 2018;20:1411-8. [PMID: 29660005 DOI: 10.1093/neuonc/noy054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
174 Chen Y, Jing Z, Luo C, Zhuang M, Xia J, Chen Z, Wang Y. Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study. Med Oncol 2012;29:324-31. [PMID: 21161444 DOI: 10.1007/s12032-010-9765-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
175 Kim WY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 2009;276:4653-64. [PMID: 19664069 DOI: 10.1111/j.1742-4658.2009.07177.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
176 Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12:1300-10. [PMID: 20716591 DOI: 10.1093/neuonc/noq099] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 12.0] [Reference Citation Analysis]
177 McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. Neuro Oncol 2016;18:1579-90. [PMID: 27106406 DOI: 10.1093/neuonc/now063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
178 Dreyfuss JM, Johnson MD, Park PJ. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 2009;8:71. [PMID: 19732454 DOI: 10.1186/1476-4598-8-71] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
179 Soto-Ortiz L, Finley SD. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol 2016;394:197-211. [PMID: 26826488 DOI: 10.1016/j.jtbi.2016.01.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
180 Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 2010;67:87-93. [PMID: 20559095 DOI: 10.1227/01.NEU.0000370918.51053.BC] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
181 Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 2011;104:639-46. [PMID: 21468776 DOI: 10.1007/s11060-011-0565-x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 8.5] [Reference Citation Analysis]
182 Yu Z, Zhao G, Zhang Z, Li Y, Chen Y, Wang N, Zhao Z, Xie G. Efficacy and safety of bevacizumab for the treatment of glioblastoma. Exp Ther Med 2016;11:371-80. [PMID: 26893618 DOI: 10.3892/etm.2015.2947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
183 Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. J Neurooncol 2016;130:591-9. [PMID: 27599828 DOI: 10.1007/s11060-016-2267-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
184 Alves ALV, Gomes INF, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM, Silva VAO. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther 2021;12:206. [PMID: 33762015 DOI: 10.1186/s13287-021-02231-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Gaonkar B, Macyszyn L, Bilello M, Sadaghiani MS, Akbari H, Atthiah MA, Ali ZS, Da X, Zhan Y, O'Rourke D, Grady SM, Davatzikos C. Automated tumor volumetry using computer-aided image segmentation. Acad Radiol 2015;22:653-61. [PMID: 25770633 DOI: 10.1016/j.acra.2015.01.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
186 Rape A, Ananthanarayanan B, Kumar S. Engineering strategies to mimic the glioblastoma microenvironment. Adv Drug Deliv Rev 2014;79-80:172-83. [PMID: 25174308 DOI: 10.1016/j.addr.2014.08.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
187 Zhang SD, Leung KL, McCrudden CM, Kwok HF. The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors. J Cancer 2015;6:812-8. [PMID: 26284131 DOI: 10.7150/jca.11975] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
188 Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 2011;104:287-91. [PMID: 21153679 DOI: 10.1007/s11060-010-0489-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
189 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
190 Baumgarten P, Blank AE, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach JP, Plate KH, Harter PN, Mittelbronn M. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 2016;18:173-83. [PMID: 26627848 DOI: 10.1093/neuonc/nov288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
191 Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clin Transl Oncol 2015;17:743-50. [PMID: 26033428 DOI: 10.1007/s12094-015-1304-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
192 Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A. Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas. Biomed Res Int 2014;2014:351252. [PMID: 24877084 DOI: 10.1155/2014/351252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
193 Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol 2013;15:480-9. [PMID: 23393208 DOI: 10.1093/neuonc/nos325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
194 Hachem LD, Mansouri A, Juraschka K, Taslimi S, Pirouzmand F, Zadeh G. Citation classics in neuro-oncology: assessment of historical trends and scientific progress. Neuro Oncol 2017;19:1158-72. [PMID: 28531344 DOI: 10.1093/neuonc/nox053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
195 Zając A, Sumorek-Wiadro J, Langner E, Wertel I, Maciejczyk A, Pawlikowska-Pawlęga B, Pawelec J, Wasiak M, Hułas-Stasiak M, Bądziul D, Rzeski W, Reichert M, Jakubowicz-Gil J. Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment. Int J Mol Sci 2021;22:5155. [PMID: 34068110 DOI: 10.3390/ijms22105155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol 2012;2012:193436. [PMID: 21804824 DOI: 10.1155/2012/193436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
197 Stockhausen MT, Kristoffersen K, Poulsen HS. The functional role of Notch signaling in human gliomas. Neuro Oncol 2010;12:199-211. [PMID: 20150387 DOI: 10.1093/neuonc/nop022] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 5.8] [Reference Citation Analysis]
198 Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep 2010;10:259-66. [PMID: 20424975 DOI: 10.1007/s11910-010-0111-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
199 Chen L, Zeng D, Xu N, Li C, Zhang W, Zhu X, Gao Y, Chen PR, Lin J. Blood–Brain Barrier- and Blood–Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases. ACS Appl Mater Interfaces 2019;11:41889-97. [DOI: 10.1021/acsami.9b14046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
200 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11:155-80. [PMID: 21453286 DOI: 10.2174/156652311795684722] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
201 Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-80. [PMID: 23485622 DOI: 10.1634/theoncologist.2012-0339] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
202 Ferraris C, Cavalli R, Panciani PP, Battaglia L. Overcoming the Blood-Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours. Int J Nanomedicine 2020;15:2999-3022. [PMID: 32431498 DOI: 10.2147/IJN.S231479] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
203 Majós C, Bruna J, Julià-Sapé M, Cos M, Camins A, Gil M, Acebes JJ, Aguilera C, Arús C. Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas. AJNR Am J Neuroradiol 2011;32:74-80. [PMID: 21030477 DOI: 10.3174/ajnr.A2251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
204 Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010;80:654-65. [PMID: 20457135 DOI: 10.1016/j.bcp.2010.04.035] [Cited by in Crossref: 136] [Cited by in F6Publishing: 134] [Article Influence: 11.3] [Reference Citation Analysis]
205 Gerges N, Fontebasso AM, Albrecht S, Faury D, Jabado N. Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm. Genome Med 2013;5:66. [PMID: 23906214 DOI: 10.1186/gm470] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
206 Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers (Basel) 2021;13:1795. [PMID: 33918704 DOI: 10.3390/cancers13081795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep 2014;16:380. [PMID: 24510742 DOI: 10.1007/s11912-014-0380-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
208 Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 2015;20:166-75. [PMID: 25568148 DOI: 10.1634/theoncologist.2014-0330] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
209 Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, Sharma R, Kavan P. Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol 2016;23:e468-71. [PMID: 27803607 DOI: 10.3747/co.23.3108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
210 Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther 2013;6:371-89. [PMID: 23620671 DOI: 10.2147/OTT.S38628] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
211 Ziegler J, Pody R, Coutinho de Souza P, Evans B, Saunders D, Smith N, Mallory S, Njoku C, Dong Y, Chen H, Dong J, Lerner M, Mian O, Tummala S, Battiste J, Fung KM, Wren JD, Towner RA. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models. Neuro Oncol 2017;19:175-85. [PMID: 27416955 DOI: 10.1093/neuonc/now147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
212 Schoenfeld JD, Dranoff G. Anti-angiogenesis immunotherapy. Hum Vaccin 2011;7:976-81. [PMID: 21860259 DOI: 10.4161/hv.7.9.16407] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
213 El Hallani S, Colin C, El Houfi Y, Idbaih A, Boisselier B, Marie Y, Ravassard P, Labussière M, Mokhtari K, Thomas JL, Delattre JY, Eichmann A, Sanson M. Tumor and endothelial cell hybrids participate in glioblastoma vasculature. Biomed Res Int 2014;2014:827327. [PMID: 24868550 DOI: 10.1155/2014/827327] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
214 Franceschi E, Ermani M, Bartolini S, Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni A, Agati R, Bacci A, Pozzati E, Morandi L, Balestrini D, Ghimenton C, Crisi G, Brandes AA. Post progression survival in glioblastoma: where are we? J Neurooncol 2015;121:399-404. [PMID: 25366365 DOI: 10.1007/s11060-014-1651-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
215 Bradley D, Rees J. Updates in the management of high-grade glioma. J Neurol 2014;261:651-4. [PMID: 23857040 DOI: 10.1007/s00415-013-7032-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
216 Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013;2:49-65. [PMID: 23750318 DOI: 10.2217/cns.12.36] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 11.4] [Reference Citation Analysis]
217 Yun TJ, Cho HR, Choi SH, Kim H, Won JK, Park SW, Kim JH, Sohn CH, Han MH. Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model. AJNR Am J Neuroradiol 2016;37:1650-6. [PMID: 27173366 DOI: 10.3174/ajnr.A4800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
218 Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 2012;14:649-57. [PMID: 22379188 DOI: 10.1093/neuonc/nos012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
219 Lutz K, Radbruch A, Wiestler B, Bäumer P, Wick W, Bendszus M. Neuroradiological response criteria for high-grade gliomas. Clin Neuroradiol 2011;21:199-205. [PMID: 21681688 DOI: 10.1007/s00062-011-0080-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
220 Butowski N. Anti-angiogenic therapy in glioma. Clin Transl Oncol 2011;13:294-300. [PMID: 21596656 DOI: 10.1007/s12094-011-0657-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
221 Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008;10:940-945. [PMID: 18708344 DOI: 10.1215/15228517-2008-061] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
222 Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 2013;73:3145-54. [PMID: 23644530 DOI: 10.1158/0008-5472.CAN-13-0011] [Cited by in Crossref: 97] [Cited by in F6Publishing: 74] [Article Influence: 10.8] [Reference Citation Analysis]
223 Kasende OE, Muya JT, de Paul N Nziko V, Scheiner S. Hydrogen bonded and stacked geometries of the temozolomide dimer. J Mol Model 2016;22:77. [PMID: 26971506 DOI: 10.1007/s00894-016-2934-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
224 Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. Oncologist 2018;23:889-e98. [PMID: 29666296 DOI: 10.1634/theoncologist.2018-0149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
225 Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KM. Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. J Neurooncol 2011;105:233-9. [PMID: 21533524 DOI: 10.1007/s11060-011-0591-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
226 Xu T, Chen J, Lu Y, Wolff JE. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 2010;10:252. [PMID: 20525214 DOI: 10.1186/1471-2407-10-252] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
227 Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 2009;19:163-70. [PMID: 19464631 DOI: 10.1016/j.semradonc.2009.02.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
228 Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev 2008;222:70-100. [PMID: 18363995 DOI: 10.1111/j.1600-065X.2008.00603.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 4.5] [Reference Citation Analysis]
229 Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130-41. [PMID: 20139170 DOI: 10.1634/theoncologist.2009-0252] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
230 Weller M, Yung WK. Bevacizumab--news from the fast lane? Neuro Oncol 2008;10:647. [PMID: 18776128 DOI: 10.1215/15228517-2008-074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
231 Hundsberger T, Hottinger AF, Roelcke U, Roth P, Migliorini D, Dietrich PY, Conen K, Pesce G, Hermann E, Pica A, Gross MW, Brügge D, Plasswilm L, Weller M, Putora PM. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. J Neurooncol 2016;126:175-83. [PMID: 26459327 DOI: 10.1007/s11060-015-1957-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
232 Lin AL, Avila EK. Neurologic Emergencies in the Patients With Cancer. J Intensive Care Med 2017;32:99-115. [PMID: 26704760 DOI: 10.1177/0885066615619582] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
233 Tamai S, Ichinose T, Tsutsui T, Tanaka S, Garaeva F, Sabit H, Nakada M. Tumor Microenvironment in Glioma Invasion. Brain Sciences 2022;12:505. [DOI: 10.3390/brainsci12040505] [Reference Citation Analysis]
234 Fisher JP, Adamson DC. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines 2021;9:324. [PMID: 33810154 DOI: 10.3390/biomedicines9030324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
235 Wang K, Wang YY, Wang JF, Ma J, Jiang T, Dai JP. Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma. AJNR Am J Neuroradiol 2016;37:629-35. [PMID: 26585263 DOI: 10.3174/ajnr.A4567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
236 Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012;14:1203-14. [PMID: 22307472 DOI: 10.1093/neuonc/nor223] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
237 Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M. The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. J Cancer Res Clin Oncol 2016;142:1825-9. [PMID: 27318492 DOI: 10.1007/s00432-016-2187-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
238 Obad N, Espedal H, Jirik R, Sakariassen PO, Brekke Rygh C, Lund-Johansen M, Taxt T, Niclou SP, Bjerkvig R, Keunen O. Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. J Cereb Blood Flow Metab 2018;38:1741-53. [PMID: 28627960 DOI: 10.1177/0271678X17714656] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
239 Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist 2015;20:952-9. [PMID: 26084808 DOI: 10.1634/theoncologist.2015-0108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
240 Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010;128:1-36. [PMID: 20546782 DOI: 10.1016/j.pharmthera.2010.04.015] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
241 Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol 2013;6:375-86. [PMID: 23927666 DOI: 10.1586/17512433.2013.811806] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
242 . Current world literature. Trauma and rehabilitation. Curr Opin Neurol 2008;21:762-4. [PMID: 18989123 DOI: 10.1097/WCO.0b013e32831cbb85] [Reference Citation Analysis]
243 Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011;5:117-29. [PMID: 21603247 DOI: 10.4137/CMO.S7232] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
244 Al-Ansari S, Jalali R, Bronckers T, Raber-Durlacher J, Logan R, de Lange J, Rozema F. The effect of a single injection of irinotecan on the development of enamel in the Wistar rats. J Cell Mol Med 2018;22:1501-6. [PMID: 29285894 DOI: 10.1111/jcmm.13415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
245 Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:3069-75. [PMID: 20479404 DOI: 10.1200/JCO.2009.26.8789] [Cited by in Crossref: 138] [Cited by in F6Publishing: 72] [Article Influence: 11.5] [Reference Citation Analysis]
246 Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101:57-66. [PMID: 20443129 DOI: 10.1007/s11060-010-0217-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 7.6] [Reference Citation Analysis]
247 Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol 2013;15:945-54. [PMID: 23788270 DOI: 10.1093/neuonc/not049] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
248 Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015;33:1197-213. [PMID: 25713439 DOI: 10.1200/JCO.2014.55.9575] [Cited by in Crossref: 108] [Cited by in F6Publishing: 61] [Article Influence: 15.4] [Reference Citation Analysis]
249 Thomas AA, Ernstoff MS, Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J 2012;18:59-68. [PMID: 22290259 DOI: 10.1097/PPO.0b013e3182431a73] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
250 Winograd E, Germano I, Wen P, Olson JJ, Ormond DR. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma. J Neurooncol 2021. [PMID: 34694567 DOI: 10.1007/s11060-021-03876-7] [Reference Citation Analysis]
251 Herrlinger U, Platten M. [Treatment of the glioma microenvironment]. Nervenarzt 2015;86:684, 686-8, 690-1. [PMID: 25962344 DOI: 10.1007/s00115-014-4225-1] [Reference Citation Analysis]
252 Rees JH. Diagnosis and treatment in neuro-oncology: an oncological perspective. Br J Radiol 2011;84 Spec No 2:S82-9. [PMID: 22433832 DOI: 10.1259/bjr/18061999] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
253 Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624-630. [PMID: 18539884 DOI: 10.1215/15228517-2008-010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
254 Artene SA, Turcu-Stiolica A, Hartley R, Ciurea ME, Daianu O, Brindusa C, Alexandru O, Tataranu LG, Purcaru SO, Dricu A. Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Onco Targets Ther 2016;9:6669-77. [PMID: 27877052 DOI: 10.2147/OTT.S112842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
255 Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 2009;14:621-36. [PMID: 19487335 DOI: 10.1634/theoncologist.2008-0272] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
256 Ling GQ, Liu YJ, Ke YQ, Chen L, Jiang XD, Jiang CL, Ye W. All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation. Mol Med Rep 2015;12:165-72. [PMID: 25760394 DOI: 10.3892/mmr.2015.3449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
257 Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010;8:221-7. [PMID: 19912518 DOI: 10.1111/j.1538-7836.2009.03690.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 5.9] [Reference Citation Analysis]
258 Dunbar EM. The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors. Curr Treat Options Oncol 2009;10:216-30. [PMID: 19381820 DOI: 10.1007/s11864-009-0091-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Peters KB, Coyle TE, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol 2011;101:155-9. [PMID: 20524043 DOI: 10.1007/s11060-010-0239-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
260 Mishra VS, Kumar N, Raza M, Sehrawat S. Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme. Oncotarget 2020;11:4754-69. [PMID: 33473259 DOI: 10.18632/oncotarget.27842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Pichler J, Marosi C. [Drug therapy of patients with recurrent glioblastoma: is there any evidence?]. Wien Med Wochenschr 2011;161:26-31. [PMID: 21181283 DOI: 10.1007/s10354-010-0863-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
262 Affronti ML, Schneider SM, Herndon JE 2nd, Schlundt S, Friedman HS. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 2014;22:1897-905. [PMID: 24570103 DOI: 10.1007/s00520-014-2136-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
263 Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 2012;17:181-202. [PMID: 22533851 DOI: 10.1517/14728214.2012.679929] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
264 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012;26:756-84. [PMID: 22508724 DOI: 10.1101/gad.187922.112] [Cited by in Crossref: 345] [Cited by in F6Publishing: 333] [Article Influence: 34.5] [Reference Citation Analysis]
265 Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol 2008;89:113-8. [PMID: 18438609 DOI: 10.1007/s11060-008-9599-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
266 Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. CNS Oncol 2014;3:1-3. [PMID: 25054891 DOI: 10.2217/cns.13.53] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Kochar AS, Madhavan M, Manjila S, Scoco A, Belle VK, Geertman RT. Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme. Asian J Neurosurg 2018;13:546-54. [PMID: 30283503 DOI: 10.4103/ajns.AJNS_266_16] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
268 Sharma A, Kumar R. Metabolic Imaging of Brain Tumor Recurrence. AJR Am J Roentgenol 2020;215:1199-207. [PMID: 32960666 DOI: 10.2214/AJR.19.22624] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Ruiz-Sánchez D, Calero MA, Sastre-Heres AJ, García MT, Hernandez MA, Martinez FM, Peña-Díaz J. Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen. Oncol Lett 2012;4:1114-8. [PMID: 23162662 DOI: 10.3892/ol.2012.861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
270 Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 2015;17:862-7. [PMID: 25572329 DOI: 10.1093/neuonc/nou350] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
271 Nossek E, Ram Z, Bokstein F, Blumenthal D. Antiangiogenesis in recurrent glioblastoma: proof of principle. Neurol Int 2009;1:e21. [PMID: 21577359 DOI: 10.4081/ni.2009.e21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2012;2:a006593. [PMID: 23209176 DOI: 10.1101/cshperspect.a006593] [Cited by in Crossref: 118] [Cited by in F6Publishing: 116] [Article Influence: 11.8] [Reference Citation Analysis]
273 El-Khouly FE, Veldhuijzen van Zanten SEM, Jansen MHA, Bakker DP, Sanchez Aliaga E, Hendrikse NH, Vandertop WP, van Vuurden DG, Kaspers GJL. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. J Neurooncol 2021;153:263-71. [PMID: 33963476 DOI: 10.1007/s11060-021-03763-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
274 Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008;17:1225-35. [PMID: 18616418 DOI: 10.1517/13543784.17.8.1225] [Cited by in Crossref: 146] [Cited by in F6Publishing: 122] [Article Influence: 10.4] [Reference Citation Analysis]
275 Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol 2012;33:556-62. [PMID: 22116105 DOI: 10.3174/ajnr.A2811] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
276 Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M. Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications. Biomed Res Int 2013;2013:353892. [PMID: 24490156 DOI: 10.1155/2013/353892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
277 Nguyen HM, Saha D. The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment. Oncolytic Virother 2021;10:1-27. [PMID: 33659221 DOI: 10.2147/OV.S268426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
278 Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. J Neurooncol 2017;131:193-9. [PMID: 27770279 DOI: 10.1007/s11060-016-2288-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
279 Tong H, Zhao K, Zhang J, Zhu J, Xiao J. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway. Drug Des Devel Ther 2019;13:317-26. [PMID: 30679904 DOI: 10.2147/DDDT.S185514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
280 Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;26:4659-65. [PMID: 18824712 DOI: 10.1200/JCO.2008.16.9235] [Cited by in Crossref: 145] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
281 Sharma RK, Calderon C, Vivas-Mejia PE. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. Front Med Technol 2021;3:678593. [PMID: 35047931 DOI: 10.3389/fmedt.2021.678593] [Reference Citation Analysis]
282 Cavaco A, Rezaei M, Niland S, Eble JA. Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. Int J Mol Sci 2017;18:E2355. [PMID: 29112161 DOI: 10.3390/ijms18112355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
283 Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012;107:133-8. [PMID: 21984064 DOI: 10.1007/s11060-011-0717-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
284 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2011;105:91-101. [PMID: 21442275 DOI: 10.1007/s11060-011-0567-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
285 Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 2009;92:45-8. [PMID: 18987781 DOI: 10.1007/s11060-008-9728-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
286 Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV. Tumor Treating Fields in Neuro-Oncological Practice. Curr Oncol Rep 2017;19:53. [PMID: 28664468 DOI: 10.1007/s11912-017-0611-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
287 Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol 2013;15:4-27. [PMID: 23136223 DOI: 10.1093/neuonc/nos273] [Cited by in Crossref: 363] [Cited by in F6Publishing: 348] [Article Influence: 36.3] [Reference Citation Analysis]
288 Jeck J, Kassubek R, Coburger J, Edenhofer S, Schönsteiner SS, Ludolph AC, Schmitz B, Engelke J, Mayer-Steinacker R, Lewerenz J, Bullinger L. Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. Ther Adv Neurol Disord 2018;11:1756285617753597. [PMID: 29403545 DOI: 10.1177/1756285617753597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
289 Friedman HS. Meet the Editorial Board Member. CCTR 2021;17:171-2. [DOI: 10.2174/157339471703210824150229] [Reference Citation Analysis]
290 Thompson G, Mills SJ, Coope DJ, O'Connor JP, Jackson A. Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol 2011;84 Spec No 2:S127-44. [PMID: 22433824 DOI: 10.1259/bjr/66316279] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
291 Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol 2010;2010:689018. [PMID: 20379377 DOI: 10.1155/2010/689018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
292 Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8:3274-3284. [PMID: 19770585 DOI: 10.4161/cc.8.20.9701] [Cited by in Crossref: 521] [Cited by in F6Publishing: 485] [Article Influence: 40.1] [Reference Citation Analysis]
293 Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, Rahmathulla G, Quinones-Hinojosa A. Advances in Brain Tumor Surgery for Glioblastoma in Adults. Brain Sci 2017;7:E166. [PMID: 29261148 DOI: 10.3390/brainsci7120166] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 19.0] [Reference Citation Analysis]
294 Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M; National Comprehensive Cancer Network. Central nervous system cancers. J Natl Compr Canc Netw 2013;11:1114-51. [PMID: 24029126 DOI: 10.6004/jnccn.2013.0132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
295 Pishko GL, Muldoon LL, Pagel MA, Schwartz DL, Neuwelt EA. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS 2015;12:5. [PMID: 25879723 DOI: 10.1186/2045-8118-12-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
296 Kim OS, Park JW, Lee ES, Yoo RJ, Kim WI, Lee KC, Shim JH, Chung HK. [18F]FET PET is a useful tool for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic glioblastoma mouse model. Lab Anim Res 2018;34:248-56. [PMID: 30671112 DOI: 10.5625/lar.2018.34.4.248] [Reference Citation Analysis]
297 Zhu B, Zhou L, Yu L, Wu S, Song W, Gong X, Wang D. Evaluation of the correlation of vasculogenic mimicry, ALDH1, KAI1 and microvessel density in the prediction of metastasis and prognosis in colorectal carcinoma. BMC Surg 2017;17:47. [PMID: 28431527 DOI: 10.1186/s12893-017-0246-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
298 Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009;18:1549-57. [PMID: 19671039 DOI: 10.1517/13543780903183528] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
299 Hu YL, Jahangiri A, Delay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res 2012;72:4294-9. [PMID: 22915758 DOI: 10.1158/0008-5472.CAN-12-1076] [Cited by in Crossref: 117] [Cited by in F6Publishing: 75] [Article Influence: 11.7] [Reference Citation Analysis]
300 Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009;27:2542-2552. [PMID: 19332720 DOI: 10.1200/jco.2008.19.9356] [Cited by in Crossref: 224] [Cited by in F6Publishing: 134] [Article Influence: 17.2] [Reference Citation Analysis]
301 Seo SH, Paul SK, Shikder M, Khanam M, Ghosh P, Hasib TA, Ahmed KA, Sikdar S, Uddin MJ, Kwon Y. An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma. Cancers (Basel) 2021;13:3221. [PMID: 34203272 DOI: 10.3390/cancers13133221] [Reference Citation Analysis]
302 Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 2008;249:268-77. [PMID: 18796682 DOI: 10.1148/radiol.2491072000] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 8.6] [Reference Citation Analysis]
303 Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 2011;102:95-103. [PMID: 20798977 DOI: 10.1007/s11060-010-0293-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
304 Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9:1087-98. [PMID: 19591631 DOI: 10.1517/14712590903124346] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
305 Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 2010;12:289-96. [PMID: 20167817 DOI: 10.1093/neuonc/nop030] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
306 Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013;19:1773-1783. [PMID: 23307858 DOI: 10.1158/1078-0432.ccr-12-1281] [Cited by in Crossref: 145] [Cited by in F6Publishing: 93] [Article Influence: 16.1] [Reference Citation Analysis]
307 Smith AW, Parashar B, Wernicke AG. Subventricular zone-associated glioblastoma: A call for translational research to guide clinical decision making. Neurogenesis (Austin) 2016;3:e1225548. [PMID: 27900341 DOI: 10.1080/23262133.2016.1225548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
308 Chen YS, Chen ZP. Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer 2014;33:74-9. [PMID: 23816560 DOI: 10.5732/cjc.012.10292] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
309 Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6. [PMID: 21149657 DOI: 10.1200/JCO.2010.30.7744] [Cited by in Crossref: 376] [Cited by in F6Publishing: 242] [Article Influence: 31.3] [Reference Citation Analysis]
310 Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML. Anti-cancer Therapies in High Grade Gliomas. Curr Proteomics 2013;10:246-60. [PMID: 24228024 DOI: 10.2174/1570164611310030007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
311 Chen X, Fang J, Wang S, Liu H, Du X, Chen J, Li X, Yang Y, Zhang B, Zhang W. A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells. Oncotarget 2014;5:1955-68. [PMID: 24722469 DOI: 10.18632/oncotarget.1885] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
312 Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011;17:4119-24. [PMID: 21531816 DOI: 10.1158/1078-0432.CCR-11-0120] [Cited by in Crossref: 105] [Cited by in F6Publishing: 60] [Article Influence: 9.5] [Reference Citation Analysis]
313 Ahir BK, Engelhard HH, Lakka SS. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma. Mol Neurobiol 2020;57:2461-78. [PMID: 32152825 DOI: 10.1007/s12035-020-01892-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
314 Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.Int J Radiat Oncol Biol Phys. 2018;100:38-44. [PMID: 29102648 DOI: 10.1016/j.ijrobp.2017.08.038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
315 Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol 2009;11:142-50. [PMID: 18772353 DOI: 10.1215/15228517-2008-077] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
316 Zhang X, Xu R, Zhang C, Xu Y, Han M, Huang B, Chen A, Qiu C, Thorsen F, Prestegarden L, Bjerkvig R, Wang J, Li X. Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination. J Exp Clin Cancer Res 2017;36:118. [PMID: 28870216 DOI: 10.1186/s13046-017-0588-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
317 Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011;6:2. [PMID: 21214925 DOI: 10.1186/1748-717X-6-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
318 Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis 2016;19:229-44. [PMID: 26961182 DOI: 10.1007/s10456-016-9503-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
319 Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 2009;284:16705-9. [PMID: 19286664 DOI: 10.1074/jbc.R900013200] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
320 Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist 2010;15:1329-34. [PMID: 21147867 DOI: 10.1634/theoncologist.2010-0105] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
321 Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future 2013;38:147-55. [PMID: 25663738 DOI: 10.1358/dof.2013.038.03.1933992] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
322 Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol 2012;39:23-34. [PMID: 21958852 DOI: 10.1016/j.nucmedbio.2011.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
323 Thomas AA, Omuro A. Current role of anti-angiogenic strategies for glioblastoma. Curr Treat Options Oncol 2014;15:551-66. [PMID: 25173555 DOI: 10.1007/s11864-014-0308-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
324 Wright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009;25:1275-82. [PMID: 19212772 DOI: 10.1007/s00381-009-0809-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
325 Youland RS, Lee JY, Kreofsky CR, Brown PD, Uhm JH, Laack NN. Modern reirradiation for recurrent gliomas can safely delay tumor progression. Neurooncol Pract 2018;5:46-55. [PMID: 31385961 DOI: 10.1093/nop/npx014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
326 Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 2012;107:351-8. [PMID: 22076449 DOI: 10.1007/s11060-011-0748-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
327 Mladkova N, Chakravarti A. Molecular profiling in glioblastoma: prelude to personalized treatment. Curr Oncol Rep 2009;11:53-61. [PMID: 19080742 DOI: 10.1007/s11912-009-0009-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
328 Ellingson BM, Wen PY, Cloughesy TF. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol 2018;20:457-71. [PMID: 29040703 DOI: 10.1093/neuonc/nox193] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
329 Ghiaseddin A, Peters KB. Use of bevacizumab in recurrent glioblastoma. CNS Oncol 2015;4:157-69. [PMID: 25906439 DOI: 10.2217/cns.15.8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
330 Yu L, Zhu B, Wu S, Zhou L, Song W, Gong X, Wang D. Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagn Pathol 2017;12:23. [PMID: 28253891 DOI: 10.1186/s13000-017-0612-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
331 Cui C, Chen X, Liu Y, Cao B, Xing Y, Liu C, Yang F, Li Y, Yang T, Hua L, Tian M, Wei Y, Gong Y, Jiang J. β1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells. J Biol Chem 2018;293:2219-30. [PMID: 29269413 DOI: 10.1074/jbc.RA117.000682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
332 Choi SW, Shin H, Sa JK, Cho HJ, Koo H, Kong DS, Seol HJ, Nam DH. Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. Cancer Med 2018;7:1774-83. [PMID: 29573206 DOI: 10.1002/cam4.1439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 2011;105:621-7. [PMID: 21744079 DOI: 10.1007/s11060-011-0631-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
334 Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986-1994. [PMID: 19920819 DOI: 10.1038/sj.bjc.6605412] [Cited by in Crossref: 145] [Cited by in F6Publishing: 124] [Article Influence: 11.2] [Reference Citation Analysis]
335 Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, Holzner B, Capper D, Preusser M, Marosi C, Oberndorfer S, Moik M, Buchroithner J, Seiz M, Tuettenberg J, Herrlinger U, Wick A, Vajkoczy P, Stockhammer G. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol 2014;16:92-102. [PMID: 24311637 DOI: 10.1093/neuonc/not161] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
336 Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2013;132:2339-48. [PMID: 23115013 DOI: 10.1002/ijc.27919] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
337 Kirkpatrick JP, Sampson JH. Recurrent malignant gliomas. Semin Radiat Oncol 2014;24:289-98. [PMID: 25219814 DOI: 10.1016/j.semradonc.2014.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
338 Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011;76:87-93. [PMID: 21205697 DOI: 10.1212/WNL.0b013e318204a3af] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
339 Yang Q, Guo C, Lin X, Luo L, He Z, Lin F, Zhang J, Chen Y, Jiang X, Ke C, Mou Y. Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis. Front Pharmacol 2021;12:804942. [PMID: 35002738 DOI: 10.3389/fphar.2021.804942] [Reference Citation Analysis]
340 Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 2008;10:e23. [PMID: 18684337 DOI: 10.1017/S1462399408000768] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
341 Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009;11:550-5. [PMID: 19332770 DOI: 10.1215/15228517-2009-006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 9.5] [Reference Citation Analysis]
342 Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81, vii. [PMID: 22520975 DOI: 10.1016/j.hoc.2012.02.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.3] [Reference Citation Analysis]
343 Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 2009;11:80-91. [PMID: 18784279 DOI: 10.1215/15228517-2008-075] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 7.5] [Reference Citation Analysis]
344 Mammoto T, Jiang A, Jiang E, Panigrahy D, Kieran MW, Mammoto A. Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am J Pathol 2013;183:1293-305. [PMID: 23928381 DOI: 10.1016/j.ajpath.2013.06.026] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
345 Nagasawa DT, Fong C, Yew A, Spasic M, Garcia HM, Kruse CA, Yang I. Passive immunotherapeutic strategies for the treatment of malignant gliomas. Neurosurg Clin N Am 2012;23:481-95. [PMID: 22748660 DOI: 10.1016/j.nec.2012.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
346 Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54. [PMID: 21321221 DOI: 10.1073/pnas.1014480108] [Cited by in Crossref: 439] [Cited by in F6Publishing: 403] [Article Influence: 39.9] [Reference Citation Analysis]
347 Xue X, Huang Y, Wang X, Wang Z, Carney RP, Li X, Yuan Y, He Y, Lin TY, Li Y. Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 2018;161:203-15. [PMID: 29421556 DOI: 10.1016/j.biomaterials.2018.01.044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
348 Sepulveda-Sanchez J, Ramos A, Hilario A, DE Velasco G, Castellano D, Garcia DE LA Torre M, Rodon J, Lahn MF. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate. Oncol Lett 2015;9:2442-8. [PMID: 26137087 DOI: 10.3892/ol.2015.3106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
349 El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010;133:973-982. [PMID: 20375132 DOI: 10.1093/brain/awq044] [Cited by in Crossref: 219] [Cited by in F6Publishing: 204] [Article Influence: 18.3] [Reference Citation Analysis]
350 Veliz I, Loo Y, Castillo O, Karachaliou N, Nigro O, Rosell R. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future? Ann Transl Med 2015;3:7. [PMID: 25705639 DOI: 10.3978/j.issn.2305-5839.2014.10.06] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
351 Blanco VM, Curry R, Qi X. SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma. Oncoscience. 2015;2:102-110. [PMID: 25859553 DOI: 10.18632/oncoscience.122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
352 Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009;115:2188-98. [PMID: 19248046 DOI: 10.1002/cncr.24213] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
353 Chowdhary MM, Ene CI, Silbergeld DL. Treatment of Gliomas: How did we get here? Surg Neurol Int 2015;6:S85-8. [PMID: 25722937 DOI: 10.4103/2152-7806.151348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
354 Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. Int J Oncol 2015;46:1883-92. [PMID: 25672376 DOI: 10.3892/ijo.2015.2891] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
355 Zhang L, Wang H. Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin. Mar Drugs 2015;13:4310-30. [PMID: 26184238 DOI: 10.3390/md13074310] [Cited by in Crossref: 85] [Cited by in F6Publishing: 68] [Article Influence: 12.1] [Reference Citation Analysis]
356 Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 2014;16:823-8. [PMID: 24596117 DOI: 10.1093/neuonc/nou021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
357 Simon T, Coquerel B, Petit A, Kassim Y, Demange E, Le Cerf D, Perrot V, Vannier JP. Direct effect of bevacizumab on glioblastoma cell lines in vitro. Neuromolecular Med 2014;16:752-71. [PMID: 25113866 DOI: 10.1007/s12017-014-8324-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
358 Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 2016;129:487-94. [PMID: 27406589 DOI: 10.1007/s11060-016-2195-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
359 Christensen K, Schrøder HD, Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol 2011;104:129-43. [PMID: 21184132 DOI: 10.1007/s11060-010-0488-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
360 Gil-Gil MJ, Mesia C, Rey M, Bruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35. [PMID: 23843722 DOI: 10.4137/CMO.S8503] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
361 Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, Germanwala AV, Elder JB, Ray-Chaudhury A, Yao Y, Gilbert MR, Lonser RR, Heiss JD, Brady RO, Mao Y, Qin J, Zhuang Z. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Oncotarget 2015;6:11882-93. [PMID: 25957416 DOI: 10.18632/oncotarget.3592] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
362 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med 2010;3:79-85. [PMID: 23226044 DOI: 10.2147/pgpm.s7940] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
363 Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010;96:423-31. [PMID: 19859666 DOI: 10.1007/s11060-009-9981-6] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 5.9] [Reference Citation Analysis]
364 Kaley T, Nolan C, Carver A, Omuro A. Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS Oncol 2013;2:413-8. [PMID: 25054664 DOI: 10.2217/cns.13.40] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
365 Nowosielski M, Recheis W, Goebel G, Güler O, Tinkhauser G, Kostron H, Schocke M, Gotwald T, Stockhammer G, Hutterer M. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011;53:291-302. [PMID: 21125399 DOI: 10.1007/s00234-010-0808-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
366 Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:119-31. [PMID: 21036812 DOI: 10.1093/neuonc/noq143] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
367 Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:1151-61. [PMID: 21856685 DOI: 10.1093/neuonc/nor079] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
368 Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G, Rosenthal MA; CABARET/COGNO investigators. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 2015;17:1504-13. [PMID: 26130744 DOI: 10.1093/neuonc/nov104] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 10.6] [Reference Citation Analysis]
369 Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 2014;6:149-70. [PMID: 24711712 DOI: 10.2147/CMAR.S54726] [Cited by in Crossref: 30] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
370 Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg 2011;114:624-32. [PMID: 20964595 DOI: 10.3171/2010.9.JNS101223] [Cited by in Crossref: 90] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
371 Weller M. [Chemotherapy for brain tumors in adult patients]. Nervenarzt 2008;79:231-41. [PMID: 18253773 DOI: 10.1007/s00115-007-2372-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
372 Spinelli C, Tawil N, Adnani L, Rak J, Choi D. Extracellular Vesicle Mediated Vascular Pathology in Glioblastoma. Subcell Biochem 2021;97:247-73. [PMID: 33779920 DOI: 10.1007/978-3-030-67171-6_10] [Reference Citation Analysis]
373 Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014;16 Suppl 7:vii2-vi11. [PMID: 25313235 DOI: 10.1093/neuonc/nou224] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
374 Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012;14:1404-12. [PMID: 23019233 DOI: 10.1093/neuonc/nos213] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
375 Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, Small D, Bicknell R, Johnston JA, Scott CJ, Olwill SA. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One 2010;5:e12543. [PMID: 20824056 DOI: 10.1371/journal.pone.0012543] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
376 Rich JN, Eyler CE. Cancer stem cells in brain tumor biology. Cold Spring Harb Symp Quant Biol 2008;73:411-20. [PMID: 19329578 DOI: 10.1101/sqb.2008.73.060] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
377 Brastianos PK, Batchelor TT. Vascular endothelial growth factor inhibitors in malignant gliomas. Target Oncol 2010;5:167-74. [PMID: 20821351 DOI: 10.1007/s11523-010-0158-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
378 Ji J, Black KL, Yu JS. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 2010;21:159-66. [PMID: 19944974 DOI: 10.1016/j.nec.2009.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
379 Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Res 2017;6:1892. [PMID: 29263783 DOI: 10.12688/f1000research.11493.1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 10.6] [Reference Citation Analysis]
380 Mrugala MM, Crew LK, Fink JR, Spence AM. Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 2012;4:1082-6. [PMID: 23162656 DOI: 10.3892/ol.2012.839] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
381 Barnes SL, Whisenant JG, Loveless ME, Yankeelov TE. Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics. 2012;4:442-478. [PMID: 23105959 DOI: 10.3390/pharmaceutics4030442] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
382 Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol 2015;129:115-31. [PMID: 25322816 DOI: 10.1007/s00401-014-1352-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
383 Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. Oncotarget 2016;7:70948-58. [PMID: 27487142 DOI: 10.18632/oncotarget.10898] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
384 Darmon I, Morisse MC, Coutte A, Blonski M, Le Rhun E, Taillandier L, Roufai DB, Desenclos C, Trudel S, Faivre JC, Blanchard N, Chauffert B, Boone M. Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. J Cancer 2017;8:1417-24. [PMID: 28638456 DOI: 10.7150/jca.18339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
385 Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) 2009;87:363-74. [PMID: 19189072 DOI: 10.1007/s00109-009-0440-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
386 Park K, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC, Lieberman FS, Lunsford LD, Kondziolka D. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study. J Neurooncol 2012;107:323-33. [DOI: 10.1007/s11060-011-0744-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
387 Timotheadou E. New agents targeting angiogenesis in glioblastoma. Chemother Res Pract 2011;2011:878912. [PMID: 22295207 DOI: 10.1155/2011/878912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
388 Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 2012;72:1773-83. [PMID: 22447568 DOI: 10.1158/0008-5472.CAN-11-3831] [Cited by in Crossref: 296] [Cited by in F6Publishing: 190] [Article Influence: 29.6] [Reference Citation Analysis]
389 Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol 2011;13:1020-9. [PMID: 21807668 DOI: 10.1093/neuonc/nor099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
390 Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229-36. [PMID: 19333229 DOI: 10.1038/nrclinonc.2009.14] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 10.2] [Reference Citation Analysis]
391 Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 2013;6:1475-506. [PMID: 24287492 DOI: 10.3390/ph6121475] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 14.7] [Reference Citation Analysis]
392 Li Y, Ali S, Clarke J, Cha S. Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. Brain Tumor Res Treat 2017;5:1-9. [PMID: 28516072 DOI: 10.14791/btrt.2017.5.1.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
393 Argyriou AA, Kalofonos HP. Molecularly targeted therapies for malignant gliomas. Mol Med 2009;15:115-22. [PMID: 19148300 DOI: 10.2119/molmed.2008.00123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
394 Ducray F, Idbaih A. Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. EMC - Neurologia 2012;12:1-14. [DOI: 10.1016/s1634-7072(12)62645-2] [Reference Citation Analysis]
395 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
396 Hottinger AF, Stupp R, Homicsko K. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer 2014;33:32-9. [PMID: 24384238 DOI: 10.5732/cjc.013.10207] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 10.1] [Reference Citation Analysis]
397 Fuso Nerini I, Cesca M, Bizzaro F, Giavazzi R. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer 2016;35:61. [PMID: 27357621 DOI: 10.1186/s40880-016-0123-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
398 Nagpal S, Harsh G, Recht L. Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemother Res Pract 2011;2011:602812. [PMID: 22312554 DOI: 10.1155/2011/602812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
399 Adam C, Pérez-López AM, Hamilton L, Rubio-Ruiz B, Bray TL, Sieger D, Brennan PM, Unciti-Broceta A. Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium-Functionalized Microdevices. Chemistry 2018;24:16783-90. [PMID: 30187973 DOI: 10.1002/chem.201803725] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
400 Jovčevska I, Kočevar N, Komel R. Glioma and glioblastoma - how much do we (not) know? Mol Clin Oncol 2013;1:935-41. [PMID: 24649273 DOI: 10.3892/mco.2013.172] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 10.3] [Reference Citation Analysis]
401 Chandra A, Rick J, Yagnik G, Aghi MK. Autophagy as a mechanism for anti-angiogenic therapy resistance. Semin Cancer Biol 2020;66:75-88. [PMID: 31472232 DOI: 10.1016/j.semcancer.2019.08.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
402 Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 2014;5:64. [PMID: 24991467 DOI: 10.4103/2152-7806.132138] [Cited by in Crossref: 92] [Cited by in F6Publishing: 114] [Article Influence: 11.5] [Reference Citation Analysis]
403 Hovey EJ, Field KM, Rosenthal MA, Barnes EH, Cher L, Nowak AK, Wheeler H, Sawkins K, Livingstone A, Phal P, Goh C, Simes J; CABARET/COGNO investigators. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neurooncol Pract 2017;4:171-81. [PMID: 31386014 DOI: 10.1093/nop/npw025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
404 Iranmahboob A, Peck KK, Brennan NP, Karimi S, Fisicaro R, Hou B, Holodny AI. Vascular Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI. J Neuroimaging 2016;26:232-9. [PMID: 26250554 DOI: 10.1111/jon.12278] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
405 Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 2009;6:513-26. [PMID: 19560741 DOI: 10.1016/j.nurt.2009.04.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
406 Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-9. [PMID: 20212229 DOI: 10.1001/archneurol.2010.16] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
407 Riina HA, Knopman J, Greenfield JP, Fralin S, Gobin YP, Tsiouris AJ, Souweidane MM, Boockvar JA. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv Neuroradiol 2010;16:71-6. [PMID: 20377982 DOI: 10.1177/159101991001600109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
408 Kim SS, Rait A, Kim E, Pirollo KF, Nishida M, Farkas N, Dagata JA, Chang EH. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8:5494-5514. [PMID: 24811110 DOI: 10.1021/nn5014484] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
409 Ishima Y, Inoue A, Fang J, Kinoshita R, Ikeda M, Watanabe H, Maeda H, Otagiri M, Maruyama T. Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide. Cancer Sci 2015;106:194-200. [PMID: 25457681 DOI: 10.1111/cas.12577] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
410 Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28:2817-2823. [PMID: 20458050 DOI: 10.1200/jco.2009.26.3988] [Cited by in Crossref: 375] [Cited by in F6Publishing: 215] [Article Influence: 31.3] [Reference Citation Analysis]